Literature DB >> 19756875

Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma.

Joshua G Barton1, John P Bois, Michael G Sarr, Christina M Wood, Rui Qin, Kristine M Thomsen, Michael L Kendrick, Michael B Farnell.   

Abstract

BACKGROUND: Preoperative serum values of CA 19-9 have been reported to be associated with survival in patients undergoing resection of pancreatic adenocarcinoma. HYPOTHESIS: Preoperative CA 19-9 levels are associated with margin and/or lymph node status in patients undergoing pancreatoduodenectomy for pancreatic carcinoma.
METHODS: We conducted a review of 143 patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma from July 2001 through April 2006 at our institution. Preoperative serum values of CA 19-9 and total bilirubin, pathologic findings, and survival were analyzed. A cutoff value for CA 19-9 (120 U/ml) was determined using a Cox proportional hazards model for survival.
RESULTS: Overall survival at 1, 3, and 5 years for patients with CA 19-9 < or = 120 U/ml was 76%, 41%, and 31%, respectively, versus 64%, 17%, and 10% for patients with CA 19-9 > 120 U/ml (p = 0.002). CA 19-9 > 120 U/ml was not associated, however, with a greater chance of an R1 or R2 resection (p = 0.86), tumor involving the SMA margin (p = 0.88), tumor at the portal vein groove (p = 0.14), or lymph node metastases (p = 0.89).
CONCLUSIONS: Our findings do not support a cutoff value for CA 19-9 that is associated with margin or lymph node involvement. Preoperative CA 19-9 < or = 120 U/ml is, however, associated with increased overall and recurrence-free survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756875     DOI: 10.1007/s11605-009-0849-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  16 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Prognostic value of CA 19-9 serum course in pancreatic cancer.

Authors:  F Safi; W Schlosser; S Falkenreck; H G Beger
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

3.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Authors:  D V Mann; R Edwards; S Ho; W Y Lau; G Glazer
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

Review 4.  Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Authors:  Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

5.  The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients.

Authors:  T Frebourg; E Bercoff; N Manchon; J Senant; J P Basuyau; P Breton; A Janvresse; P Brunelle; J Bourreille
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

6.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

7.  An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective.

Authors:  T Temudom; M G Sarr; M G Douglas; M B Farnell
Journal:  Pancreas       Date:  1995-10       Impact factor: 3.327

8.  Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.

Authors:  C E Forsmark; L Lambiase; S B Vogel
Journal:  Pancreas       Date:  1994-11       Impact factor: 3.327

9.  Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.

Authors:  M Yasue; J Sakamoto; S Teramukai; T Morimoto; K Yasui; N Kuno; K Kurimoto; Y Ohashi
Journal:  Pancreas       Date:  1994-11       Impact factor: 3.327

10.  Clinical usefulness of CA-19-9 in pancreatic carcinoma.

Authors:  A Nakao; K Oshima; S Nomoto; S Takeda; T Kaneko; T Ichihara; T Kurokawa; T Nonami; H Takagi
Journal:  Semin Surg Oncol       Date:  1998 Jul-Aug
View more
  35 in total

1.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

2.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

3.  Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.

Authors:  Katie Partyka; Kevin A Maupin; Randall E Brand; Brian B Haab
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

4.  Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Authors:  G Lakatos; A Petranyi; A Szűcs; L Nehéz; L Harsanyi; P Hegyi; G Bodoky
Journal:  Pathol Oncol Res       Date:  2017-01-06       Impact factor: 3.201

Review 5.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

6.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

Review 7.  Screening for pancreatic cancer: why, how, and who?

Authors:  Katherine E Poruk; Matthew A Firpo; Douglas G Adler; Sean J Mulvihill
Journal:  Ann Surg       Date:  2013-01       Impact factor: 12.969

8.  Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.

Authors:  Mohammed Aldakkak; Kathleen K Christians; Ashley N Krepline; Ben George; Paul S Ritch; Beth A Erickson; Fabian M Johnston; Douglas B Evans; Susan Tsai
Journal:  HPB (Oxford)       Date:  2015-08-10       Impact factor: 3.647

9.  The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.

Authors:  Jayabal Pandiaraja; Subramanian Viswanathan; Thomas Babu Antomy; Sathyamoorthy Thirumuruganand; Dhandapani Subramanian Kumaresan
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 10.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.